E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
post-resectional liver failure |
|
E.1.1.1 | Medical condition in easily understood language |
post-resectional liver failure |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
to assess if xenon is superior in order to decrease the incidence of a post-resectional liver failure in contrast to desflurane |
|
E.2.2 | Secondary objectives of the trial |
if xenon is superior regarding the outcomes (like mortality, length of hospital stay, postoperative adverse events, maximum liver function postoperative) compared to desflurane |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. ≥ 3 segment resection 2. ≥ 18 years 3. Both gender 4. ASA I-III 5. Written informed consent prior to study participation
|
1. ≥ 3 Teile der Leber zu entfernen 2. ≥ 18 Jahre 3. Männlich oder weiblich 4. ASA I-III 5. schriftliche Einwilligung für die Teilnahme an der Studie
|
|
E.4 | Principal exclusion criteria |
1. Severe pulmonary or airway disease 2. Severe liver disease, accompanied by a Child–Pugh class >A 3. Allergy/hypersensitivity to study medications 4. ASA > III 5. Patients susceptible to malignant hyperthermia 6. Women who are pregnant, breast-feeding or women of childbearing potential not using adequate contraceptive methods 7. Patients with elevated intracranial pressure 8. Patients legally unable to give written informed consent. 9. Patients with preeclampsia or eclampsia 10. Patients with a risk of high oxygen demand 11. Patients with seriously impaired cardiac function 12. All contraindications for xenon anesthesia according to the summary of product characteristics LENOXe 13. Patient participates in a parallel interventional clinical trial during this study or receives an investigational drug within 30 days prior to inclusion into this study
|
1. schwere Lungen- oder Luftwegerkrankung 2. schwere Lebererkrankung, begleitet von einem Child-Pugh-Stadium > A 3. allergisch/überempfindlich gegen die Studienmedikation 4. ASA ≥ IV 5. Anfällig für bösartige Hyperthermie 6. Schwangerschaft, stillende Frau 7. Patienten mit erhöhtem Hirndruck 8. einwilligungsunfähig sind und / oder nicht in der Lage sind Wesen, Bedeutung und Tragweite der Studie zu verstehen und ihre Einwilligung schriftlich abzugeben 9. Präeklampsie oder Eklampsie 10. Risiko eines hohen Sauerstoffbedarfs 11. Schwere beeinträchtigte Herzfunktion 12. Alle Kontraindikationen für das Narkosemittel Xenon bzgl. der Fachinformation von LENOXe® 13. Patienten nehmen gleichzeitig an einer anderen interventionellen klinischen Studie teil oder haben eine Prüfmedikation innerhalb von 30 Tagen vor Einschluss in diese Studie erhalten
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
postoperative liver injury and function after major liver resection until day 7 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Perioperative laboratory data Pathohistology of the resected liver tissue Asservation of remnants of the resected liver tissue for further laboratory analyzes Weight of resected liver tissue normalized to body weight (%BW) and planimetry with computer tomography Intraoperative and postoperative blood loss Optional LiMAx test POD 42 Quantity of infused crystalloids, colloids, units of transfused packed red blood cells, fresh frozen plasma and platelet concentrates Postoperative adverse events Mortality Length of stay
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |